Similar articles

• Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines.

  Jinushi M, Hodi FS, Dranoff G. Jinushi M, et al. Immunol Rev. 2008 Apr;222:287-98. doi: 10.1111/j.1600-065X.2008.00618.x. Immunol Rev. 2008. PMID: 18364009 Review.
• Pilot study of granulocyte-macrophage colony-stimulating factor and interleukin-2 as immune adjuvants for a melanoma peptide vaccine.

  Block MS, Suman VJ, Nevala WK, Kottschade LA, Creagan ET, Kaur JS, Quevedo JF, McWilliams RR, Markovic SN. Block MS, et al. Melanoma Res. 2011 Oct;21(5):438-45. doi: 10.1097/CMR.0b013e32834640c0. Melanoma Res. 2011. PMID: 21697748 Clinical Trial.
• Granulocyte-macrophage colony stimulating factor: an adjuvant for cancer vaccines.

  Chang DZ, Lomazow W, Joy Somberg C, Stan R, Perales MA. Chang DZ, et al. Hematology. 2004 Jun;9(3):207-15. doi: 10.1080/10245330410001701549. Hematology. 2004. PMID: 15204102 Review.
• Long-term idiotype vaccination combined with interleukin-12 (IL-12), or IL-12 and granulocyte macrophage colony-stimulating factor, in early-stage multiple myeloma patients.

  Hansson L, Abdalla AO, Moshfegh A, Choudhury A, Rabbani H, Nilsson B, Osterborg A, Mellstedt H. Hansson L, et al. Clin Cancer Res. 2007 Mar 1;13(5):1503-10. doi: 10.1158/1078-0432.CCR-06-1603. Clin Cancer Res. 2007. PMID: 17332295 Clinical Trial.
• Diverse CD8+ T-cell responses to renal cell carcinoma antigens in patients treated with an autologous granulocyte-macrophage colony-stimulating factor gene-transduced renal tumor cell vaccine.

  Zhou X, Jun DY, Thomas AM, Huang X, Huang LQ, Mautner J, Mo W, Robbins PF, Pardoll DM, Jaffee EM. Zhou X, et al. Cancer Res. 2005 Feb 1;65(3):1079-88. Cancer Res. 2005. PMID: 15705910